Autoantibodies and Biomarker Discovery - Proteomic and Metabolomic Approaches to Biomarker Discovery - page 366

62. Iversen OJ, Lysvand H, Hagen L. The autoantigen Pso

p27: a post-translational modi

75. Wandall HH, Blixt O, Tarp MA, et al. Cancer bio-
markers de cation of SCCA mole-

cules. Autoimmunity 2011;44(3):229

ned by autoantibody signatures to aberrant
O-glycopeptide epitopes. CancerRes 2010;70(4):1306 34.

63. Le Naour F, Brichory F, Misek DE, Brechot C,
Hanash SM, Beretta L. A distinct repertoire of auto-
antibodies in hepatocellular carcinoma identi

13.
76. Yan Y, Phan L, Yang F, et al. A novel mechanism of
alternative promoter and splicing regulates

e e

the

ed by
proteomic analysis. Mol Cell Proteomics 2002;1(3):
197

epitope generation of tumor antigen CML66-L.

60.
77. Lernmark A. Autoimmune diseases: are markers
ready for prediction? J Clin Invest 2001;108(8):1091

J Immunol 2004;172(1):651

e

203.
64. Maggi E, Finardi G, Poli M, et al. Speci

e

city of auto-
antibodies against oxidized LDL as an additional
marker for atherosclerotic risk. Coron Artery Dis 1993;
4(12):1119

6.

e

78. Wenzlau JM, Juhl K, Yu L, et al. The cation ef ux

transporter ZnT8 (Slc30A8) is a major autoantigen in
human type 1 diabetes. Proc Natl Acad Sci USA 2007;
104(43):17040

22.
65. Malmegrim KC, Pruijn GJ, van Venrooij WJ. The fate
of the U1 snRNP autoantigen during apoptosis:
implications for systemic autoimmunity. Isr Med Assoc
J 2002;4(9):706

e

5.
79. Koike H, Tanaka F, Sobue G. Paraneoplastic neurop-
athy: wide-ranging clinicopathological manifestations.
Curr Opin Neurol 2011;24(5):504

e

12.
66. Mamula MJ, Gee RJ, Elliott JI, et al. Isoaspartyl post-
translational modi

e 10.

80. Ponomarenko NA, Durova OM, Vorobiev II , et al.
Autoantibodies to myelin basic protein catalyze site-
speci

e

cation triggers autoimmune
responses to self-proteins. J Biol Chem 1999;274(32):
22321

c degradation of their antigen. Proc Natl Acad
Sci USA 2006;103(2):281 7.

67. Mor-Vaknin N, Kappes F, Dick AE, et al. DEK in the
synovium of patients with juvenile idiopathic arthritis:
characterization of DEK antibodies

e 6.

81. Gabibov AG, Belogurov Jr AA, Lomakin YA, et al.
Combinatorial antibody library from multiple scle-
rosis patients reveals antibodies that cross-react with
myelin basic protein and EBV antigen. FASEB J 2011;
25(12):4211

e

and post-

translational modi cation of the DEK autoantigen.

Arthritis Rheum 2011;63(2):556 67.

68. Mydel P, Wang Z, Brisslert M, et al. Carbamylation-
dependent activation of T cells: a novel mechanism in
the pathogenesis of autoimmune arthritis. J Immunol
2010;184(12):6882

e 21.

82. Kimura A, Sakurai T, Koumura A, et al. High preva-
lence of autoantibodies against phosphoglycerate
mutase 1 in patients with autoimmune central nervous
system diseases. J Neuroimmunol 2010;219(1-2):105

e

90.
69. Nakatsugawa M, Hirohashi Y, Torigoe T, et al. Novel
spliced form of a lens protein as a novel lung cancer
antigen, Lengsin splicing variant 4. Cancer Sci 2009;
100(8):1485

8.
83. Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-
1-directed autoimmunity is identi

e e

ed in multiple
sclerosis patients andmediates graymatter pathology in
animals. Proc Natl Acad Sci USA 2009;106(20):8302 93.

70. Neugebauer KM, Merrill JT, Wener MH, Lahita RG,
Roth MB. SR proteins are autoantigens in patients
with systemic lupus erythematosus. Importance of
phosphoepitopes. Arthritis Rheum 2000;43(8):1768

7.

e e

84. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):
225 49.

85. Sondak VK, Smalley KS, Kudchadkar R, Grippon S,
Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011;
10(6):411

e

78.
71. Pedchenko V, Vanacore R, Hudson B. Goodpasture

e

s
disease: molecular architecture of the autoantigen
provides clues to etiology and pathogenesis. Curr Opin
Nephrol Hypertens 2011;20(3):290

'

2.
86. Higano CS, Small EJ, Schellhammer P,

e

et al.

6.
72. Soussi T. p53 Antibodies in the sera of patients with
various types of cancer: a review. Cancer Res 2000;
60(7):1777

Sipuleucel-T. Nat Rev Drug Discov 2010;9(7):513 4.

e e

87. Grivennikov SI, Greten FR, Karin M. Immunity,

99.
88. Bei R, Masuelli L, Palumbo C, Modesti M, Modesti A.
A common repertoire of autoantibodies is shared by
cancer and autoimmune disease patients: In

in ammation, and cancer. Cell 2010;140(6):883 e

88.
73. Terzoglou AG, Routsias JG, Avrameas S,
Moutsopoulos HM, Tzioufas AG. Preferential recog-
nition of the phosphorylated major linear B-cell
epitope of La/SSB 349-368 aa by anti-La/SSB auto-
antibodies from patients with systemic autoimmune
diseases. Clin Exp Immunol 2006;144(3):432

e

amma-
tion in their induction and impact on tumor growth.
Cancer Lett 2009;281(1):8 23.

89. Rauser S, Langer R, Tschernitz S, et al. High number
of CD45RO

e

9.
74. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP
antibodies: the past, the present and the future. Nat
Rev Rheumatology 2011;7(7):391

e ltrating lymphocytes is an

independent prognostic factor in non-metastasized
(stage

þ tumor in

IIA) esophageal adenocarcinoma. BMC
Cancer 2010;10:608.

I e

8.

e